logo
Plus   Neg
Share
Email

Morningstar To Pay Business Logic $61 Mln To Settle Dispute

Investment research company Morningstar Inc (MORN) Thursday agreed to settle its intellectual property dispute with Business Logic Holding Corp.

As per the terms of the agreement, Morningstar has secured a license to the intellectual property and will pay Business Logic $61 million.

Morningstar will record the expense in the second quarter of 2014.

The lawsuit stems from a 2003 contract between Business Logic and Ibbotson Associates, which is now a unit of Morningstar.

Business Logic gave Ibbotson the right to embed and combine its software with Ibbotson's software to develop Advice by Ibbotson, the company's advice and managed account platform for retirement plan participants.

Morningstar acquired Ibbotson in 2006. When the contract between Ibbotson and Business Logic ended in 2009, Ibbotson replaced the Business Logic software with its own. Business Logic claimed that Morningstar and Ibbotson breached the contract and used Business Logic trade secrets to develop the new software. Business Logic filed suit against Morningstar and Ibbotson in 2009 and Morningstar and Ibbotson contested the claims.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Video streaming giant Netflix said it will donate 1 million euros to Audiens, the social protection group of the French cultural sector, to help launch a COVID-19 emergency relief fund to support workers in the French television and cinema industry. Netflix and Audiens said they have created the new COVID-19 Film and TV Emergency Relief Fund to help the hardest hit workers in the industry. Major U.S. retail container ports are estimated to report a five-year low for imports in March as consumer demand has been impacted with millions of Americans out of work amid the coronavirus (COVID-19) outbreak, according to a report by the National Retail Federation or NRF. The U.S. Food and Drug Administration has issued warning letters to three sellers of fraudulent COVID-19 products. There are currently no approved preventatives or treatments for COVID-19, the FDA said in a statement.
Follow RTT
>